STOCK TITAN

CVRx, Inc. - $CVRX STOCK NEWS

Welcome to our dedicated page for CVRx news (Ticker: $CVRX), a resource for investors and traders seeking the latest updates and insights on CVRx stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CVRx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CVRx's position in the market.

Rhea-AI Summary
CVRx, Inc. (NASDAQ: CVRX) to Present at 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
-
Rhea-AI Summary
CVRx, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure to New Technology APC 1580 in the 2024 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. The new payment amount is $45,000, effective from January 1, 2024. This reassignment is expected to increase access to the therapy for Medicare patients with heart failure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.3%
Tags
none
-
Rhea-AI Summary
CVRx, Inc. announces financial results for Q3 2023 with total revenue of $10.5 million, a 70% increase YoY. U.S. Heart Failure revenue increases by 92% YoY to $9.4 million. Active implanting centers in the U.S. grow to 159, a 75% increase since September 2022. Cash used in operating and investing activities for Q3 2023 was $8.2 million. CMS Advisory Panel recommends higher payment level for Barostim in 2024. Company provides updated business outlook for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
Rhea-AI Summary
CVRx to release Q3 2023 financial results on October 26th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.49%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
conferences
-
Rhea-AI Summary
CVRx, Inc. announces its financial and operating results for Q2 2023, reporting total revenue of $9.5 million, an 89% increase YoY. U.S. Heart Failure revenue grew by 119% YoY. The company filed a PMA supplement with the FDA for Barostim indication expansion. Active implanting centers in the U.S. increased by 97% since June 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.21%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.78%
Tags
none
CVRx, Inc.

Nasdaq:CVRX

CVRX Rankings

CVRX Stock Data

174.06M
10.98M
9.86%
77.66%
3.97%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MINNEAPOLIS

About CVRX

cvrx is a private company located in minneapolis, minnesota. the company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. the barostim neo™ uses cvrx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. the barostim neo can be adjusted to meet each patient’s individual therapy needs.